It is a chimeric mouse-human monoclonal antibody to the ? chain (CD25) of the IL-2 receptor of T cells. More
It is a chimeric mouse-human monoclonal antibody to the ? chain (CD25) of the IL-2 receptor of T cells.
Basiliximab-functions as an IL-2 receptor antagonist.
Simulect
Basiliximab, a chimeric murine/human monoclonal antibody, blocks the α-chain of the interleukin-2 receptor complex on the surface of activated T-lymphocytes. Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
The recommended is 20 mg within 2 hours before transplant, repeat once 4 days later.
Prophylaxis of acute graft rejection in renal transplantation
Peripheral oedema, hypertension, atrial fibrillation; fever, headache, insomnia, pain; wound complication, acne, hyperglycaemia, hypokalaemia, hyperuricaemia, hypercholesterolaemia; hypophosphataemia, GI effects; UTI; anaemia; tremor; dyspnoea, infection. Rarely, hypersensitivity and anaphylactoid-type reactions.
Immunosuppressives other than ciclosporin and corticosteroids may increase the potential for over-immunosuppression
Hypersensitivity to basiliximab and murine proteins
Store it in an air tight container, in refrigerator.
143801.3 Da
C6378H9844N1698O1997S48
179045-86-4
Pregnancy and lactation. Re-exposure to a subsequent course of therapy of basiliximab
